Lipid formulations of amphotericin b as first-line treatment of zygomycosis

Clinical Microbiology and Infection

Volumn 15, Issue SUPPL. 5, 2009, Pages 87-92

  Petrikkos, G L ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

ABCD; ABLC; AmB; Amphotericin B; Amphotericin B colloidal dispersion; Amphotericin B lipid complex; L AmB; Liposomal amphotericin B; Mucormycosis; Polyene; Treatment; Zygomycosis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; POSACONAZOLE;

BLOOD BRAIN BARRIER; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DEBRIDEMENT; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG PENETRATION; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOCOMPROMISED PATIENT; MUCORMYCOSIS; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RHIZOPUS ORYZAE; SURVIVAL RATE;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; HUMANS; ZYGOMYCOSIS;

EID: 70349980691     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.02987.x     Document Type: Review

References (89)

1. Gonzalez CE, Rinaldi MG, Sugar AM. Zygomycosis. Infect Dis Clin North Am 2002, 16:895-914.
2. Ibrahim AS, Edwards JE, Filler SG, Dismukes WE, Pappas PG, Sobel JD. Zygomycosis. Medical Mycology 2003, 241-251. In, eds, New York, NY, Oxford Press
3. Sugar AM, Mandell GL, Bennett JE, Dolin R. Agents of mucormycosis and related species. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases 2005, 2973-2984. In, eds, Philadelphia, PA, Elsevier Churchill Livingstone
4. Chayakulkeeree M, Perfect JR. Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis 2006, 25:215-229.
5. Richardson MD, Warnock DW, Richardson MD, Warnock DW. Mucormycosis. Fungal Infection Diagnosis and Management 2003, 230-240. In, eds, Oxford, Blackwell
6. Maertens J, Demuynck H, Verbeken EK. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant 1999, 24:307-312.
7. Liapis CD, Petrikkos GL, Paraskevas KI. External iliac artery stent mucormycosis in a renal transplant patient. Ann Vasc Surg 2006, 20:253-257.
8. Roden MM, Zaoutis TE, Buchanan WL. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005, 41:634-653.
9. Pagano L, Girmenia C, Mele L. Infections caused by filamentous fungi in patients with haematologic malignancies. A report of 391 cases by GIMEMA Infection Programme. Haematologica 2001, 86:862-870.
10. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000, 13:236-301.
11. Van den Saffele JK, Boelaert JR. Zygomycosis in HIV-positive patients: a review of the literature. Mycoses 1996, 39:77-84.
12. Greenberg RN, Scott LJ, Vaughn HH, Ribes JA. Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Curr Opin Infect Dis 2004, 17:517-525.
13. Johnson PC, Satterwhite TK, Monheit JE, Parks D. Primary cutaneous mucormycosis in trauma patients. J Trauma 1987, 27:437-441.
14. Cooter RD, Lim IS, Ellis DH, Leitch IO. Burn wound zygomycosis caused by Apophysomyces elegans. J Clin Microbiol 1990, 28:2151-2153.
15. Petrikkos G, Skiada A, Sambatakou H. Mucormycosis: 10-year experience at a tertiary care centre in Greece. Eur J Clin Microbiol Infect Dis 2003, 22:753-756.
16. Boelaert JR, Fenves AZ, Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis 1991, 18:660-667.
17. Marty FM, Cosimi L A, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of haematopoietic stem cell transplants. N Engl J Med 2004, 350:950-952.
18. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004, 39:743-746.
19. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M. Invasive zygomycosis in haematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004, 39:584-587.
20. Oren I. Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin Infect Dis 2005, 40:770-771.
21. Kontoyiannis DP, Lionakis MS, Lewis RE. Zygomycosis in a tertiary care cancer centre in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005, 191:1350-1359.
22. Vigouroux S, Morin O, Moreau P. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with haematologic disease: attention required. Clin Infect Dis 2005, 40:e35-e37.
23. Trifilio S, Singhal S, Williams S. Breakthrough fungal infections after allogeneic haematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007, 40:451-456.
24. Kauffman CA. Zygomycosis: re-emergence of an old pathogen. Clin Infect Dis 2004, 39:588-590.
25. Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 2004, 10(suppl 1):31-47.
26. Rogers TR. Treatment of zygomycosis: current and new options. J Antimicrob Chemother 2008, 61(suppl 1):35-39.
27. Gleissner B, Schilling A, Anagnostopolous I, Siehl I, Thiel E. Improved outcome of zygomycosis in patients with haematological diseases?. Leuk Lymphoma 2004, 45:1351-1360.
28. Lee FY, Mossad SB, Adal KA. Pulmonary mucormycosis: the last 30 years. Arch Intern Med 1999, 159:1301-1309.
29. Meyer RD, Rosen P, Armstrong D. Phycomycosis complicating leukaemia and lymphoma. Ann Intern Med 1972, 77:871-879.
30. Straatsma BR, Zimmerman LE, Gass JDM. Phycomycosis, a clinicopathologic study of 51 cases. Lab Invest 1962, 11:963-985.
31. Bhaduri S, Kurrle E, Vanek E, Spanel R. Mucormycosis in the immunocompromised host. Infection 1983, 11:170-172.
32. Hanley P. Rhinocerebral zygomycosis treated with amphotericin B. Postgrad Med J 1978, 54:338-339.
33. Gonzalez CE, Couriel DR, Walsh TJ. Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor. Clin Infect Dis 1997, 24:192-196.
34. Maury S, Leblanc T, Feuilhade M, Molina JM, Schaison G. Successful treatment of disseminated mucormycosis with liposomal amphotericin B and surgery in a child with leukaemia. Clin Infect Dis 1998, 26:200-202.
35. Weng DE, Wilson WH, Little R, Walsh TJ. Successful medical management of isolated renal zygomycosis: case report and review. Clin Infect Dis 1998, 26:601-605.
36. Walsh TJ, Hiemenz JW, Seibel NL. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998, 26:1383-1396.
37. Gariria JM, Grouskopf LA, Barnes R, Root RK. Successful treatment of rhinocerebral zygomycosis: a combined-strategy approach. Clin Infect Dis 1999, 28:160-161.
38. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KVI. Zygomycosis in the 1990s in a tertiary care cancer centre. Clin Infect Dis 2000, 30:851-856.
39. Barron MA, Lay M, Madinger NE. Surgery and treatment with high-dose liposomal amphotericin B for eradication of craniofacial zygomycosis in a patient with Hodgkin's disease who had undergone allogeneic haematopoietic stem cell transplantation. J Clin Microbiol 2005, 43:2012-2014.
40. DeSousa R, MacKinnon S, Spagnolo SV, Fossieck BE. Treatment of localized pulmonary phycomycosis. South Med J 1979, 72:609-612.
41. Medoff G, Kobayashi GS. Pulmonary mucormycosis. N Engl J Med 1972, 286:86-87.
42. Ng TTC, Campbell CK, Rothera M, Houghton JB, Hughes D, Denning DW. Successful treatment of sinusitis caused by Cunninghamella bertholletiae. Clin Infect Dis 1994, 19:313-316.
43. Weitzman I, Della-Latta P, Housey G, Rebatta G. Mucor ramosissimus isolated from a thigh lesion. J Clin Microbiol 1993, 31:2523-2525.
44. Ibrahim AS, Edwards JEJ, Filler SG, Dismukes WE, Pappas PG, Sobel JD. Zygomycosis. Clinical Mycology 2003, 241-251. In, eds, New York, NY, Oxford University Press
45. Wertlake PT, Butler WT, Hill GJ, Utz JP. Nephrotoxic tubular damage and calcium deposition following amphotericin B therapy. Am J Pathol 1963, 43:449-457.
46. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990, 12:308-329.
47. Hiemenz JWR, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996, 22(suppl 2):133-144.
48. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998, 27:603-618.
49. Kofteridis DP, Karabekios S, Panagiotides JG. A successful treatment of rhinocerebral mucormycosis with liposomal amphotericin B and surgery in two diabetic patients with renal dysfunction. J Chemother 2003, 15:282-286.
50. Herbrecht R, Letscher-Bru V, Bowden RA. Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis 2001, 20:460-466.
51. Crompton JA, Alexander D, Somerville T, Shihab FS. Lipid-based amphotericin in pulmonary zygomycosis: safety and efficacy of high exposure in a renal allograft recipient. Transpl Infect Dis. 2004, 6:183-187.
52. Perfect JR. Use of newer antifungal therapies in clinical practice: what do the data tell us?. Oncology (Williston Park) 2004, 18:15-23.
53. Spellberg B, Witt MD, Beck CK. Amphotericin B: is a lipid-formulation gold standard feasible?. Clin Infect Dis 2004, 38:304-307.
54. Chayakulkeeree M, Ghannoum MA, Perfect JR. Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis 2006, 25:215-229.
55. Fisher EW, Toma A, Fisher PH, Cheesman AD. Rhinocerebral mucormycosis: use of liposomal amphotericin B. J Laryngol Otol 1991, 105:575-577.
56. Wali YA, al Lamki Z, al Kindi H. Case report. Successful outcome of invasive nasal sinus zygomycosis in a child with relapsed acute lymphoblastic leukaemia due to liposomal amphotericin B. Mycoses 2001, 44:195-199.
57. Serna JH, Wagner A, Dosekun AK. Successful treatment of mucormycosis peritonitis with liposomal amphotericin B in a patient on longterm peritoneal dialysis. Am J Kidney Dis 2003, 42:14-17.
58. Georgala A, Vekemans M, Husson M. Zygomycosis in the immunocompromised patient: a case report. Acta Biomed 2006, 77(suppl 2):5-9.
59. Righi E, Giacomazzi CG, Bassetti M. Soft-tissue infection with Absidia corymbifera and kidney complications in an AIDS patient. Med Mycol 2007, 45:637-640.
60. Handzel O, Landau Z, Halperin D. Liposomal amphotericin B treatment for rhinocerebral mucormycosis: how much is enough?. Rhinology 2003, 41:184-186.
61. Munir N, Jones NS. Rhinocerebral mucormycosis with orbital and intracranial extension: a case report and review of optimum management. J Laryngol Otol 2007, 121:192-195.
62. Revankar SG, Hasan MS, Smith JW. Cure of disseminated zygomycosis with cerebral involvement using high dose liposomal amphotericin B and surgery. Med Mycol 2007, 45:183-185.
63. Cagatay AA, Oncu SS, Calangu SS, Yildirmak TT, Ozsut HH, Evalsoy HH. Rhinocerebral mucormycosis treated with 32 gram liposomal amphotericin B and incomplete surgery: a case report. BMC Infect Dis 2001, 1:22.
64. Revankar S, Hasan S, Smith J. Cure of disseminated zygomycosis with cerebral involvement using high dose liposomal amphotericin B and surgery. Med Mycol 2007, 45:183-185.
65. Cordonier C, Bresnic M, Ebrachimi R. Liposomal amphotericin B (Ambisome) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pool analysis. Mycoses 2007, 50:205-209.
66. Ibrahim AS, Avanessian V, Spellberg B, Edwards JE. Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob Agents Chemother 2003, 47:3343-3344.
67. Bandettini R, Tuo P, Tamisani AM, Di Mario E, Mantero E. Severe cutaneous zygomycosis: evaluation of treatment with high doses of liposomal amphotericin B in a one-year-old child. J Chemother 2007, 19:347-349.
68. Salonen JH. Successful management of cerebral and pulmonary mucormycosis with liposomal amphotericin B in a 28-year-old woman with acute lymphoblastic leukaemia. Acta Biomed 2006, 77(suppl 2):28-31.
69. Wehl G, Hoegler W, Kropshofer G, Meister B, Fink FM, Heitger A. Rhinocerebral mucormycosis in a boy with recurrent acute lymphoblastic leukaemia: longterm survival with systemic antifungal treatment. J Pediatr Hematol Oncol 2002, 24:492-494.
70. Gubarev N, Separovic J, Gasparovic V, Jelic I. Successful treatment of mucormycosis endocarditis complicated by pulmonary involvement. Thorac Cardiovasc Surg 2007, 55:257-258.
71. Perfect JR. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis 2005, 40(suppl 6):401-408.
72. Strasser MD, Kennedy RJ, Adam RD. Rhinocerebral mucormycosis. Therapy with amphotericin B lipid complex. Arch Intern Med 1996, 156:337-339.
73. Gollard R, Rabb C, Larsen R, Chandrasoma P. Isolated cerebral mucormycosis: case report and therapeutic considerations. Neurosurgery 1994, 34:174-177.
74. Larkin JA, Montero JA. Efficacy and safety of amphotericin B lipid complex for zygomycosis. Infect Med 2003, 20:201-206.
75. Forrest GN, Mankes K. Outcomes of invasive zygomycosis infections in renal transplant recipients. Transpl Infect Dis 2007, 9:161-164.
76. Moses AE, Rahav G, Barenholz Y. Rhinocerebral mucormycosis treated with amphotericin B colloidal dispersion in three patients. Clin Infect Dis 1998, 26:1430-1433.
77. Noskin G, Pietrelli L, Gurwith M, Bowden R. Treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients. Bone Marrow Transplant 1999, 23:697-703.
78. Ibrahim AS, Gebremariam T, Husseiny MI. Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob Agents Chemother 2008, 52:1573-1576.
79. Dannaoui E, Afeltra J, Meis JF, Verweij PE. In vitro susceptibilities of Zygomycetes to combinations of antimicrobial agents. Antimicrob Agents Chemother 2002, 46:2708-2711.
80. Richardson M. AmBisome: adds to the body of knowledge and familiarity of use. Acta Biomed 2006, 77(suppl 4):3-11.
81. Spellberg B, Edwards J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005, 18:556-569.
82. Walsh TJ, Goodman JL, Pappas P. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001, 45:3487-3496.
83. Cornely OA, Maertens J, Bresnik M. Liposomal amphotericin B as initial therapy for invasive mould infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007, 44:1289-1297.
84. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with haematologic malignancy who have zygomycosis. Clin Infect Dis 2008, 47:503-509.
85. Johnson MD, Perfect JR. Combination antifungal therapy: what can and should we expect?. Bone Marrow Transplant 2007, 40:297-306.
86. Vazquez L, Mateos JJ, Sanz-Rodriguez C, Perez E, Caballero D, San Miguel JM. Successful treatment of rhinocerebral zygomycosis with a combination of caspofungin and liposomal amphotericin B. Haematologica 2005, 90(suppl 12):39.
87. Rickerts V, Atta J, Herrmann S. Successful treatment of disseminated mucormycosis with a combination of liposomal amphotericin B and posaconazole in a patient with acute myeloid leukaemia. Mycoses 2006, 49(suppl 1):27-30.
88. Spellberg B, Fu Y, Edwards J, Ibrahim AS. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother 2005, 49:830-832.
89. Kwon DS, Mylonakis E. Posaconazole: a new broad-spectrum antifungal agent. Expert Opin Pharmacother 2007, 8:1167-1178.